Development asset linked to Orion Laboratories Pty in public FDA and regional records.
pharma · Metastatic castration-resistant prostate cancer. · short-term treatment of insomnia
Orion Laboratories Pty
Orion Laboratories Pty.
Orion Laboratories Pty drug portfolio — 20 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Baton Rouge, USA HQ
2008 Founded
52 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Baton Rouge, USA
- Founded
- 2008
- Employees
- 52
- Programs
- 9
- Drugs
- 20
- Patents
- 0
Orion Laboratories Pty pipeline
Portfolio lens on 20 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Orion Laboratories Pty drug portfolio — 20 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Orion Laboratories Pty in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
Development asset linked to Orion Laboratories Pty in public FDA and regional records.
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
ipilimumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Cytotoxic T-lymphocyte protein 4.
- Target
- Cytotoxic T-lymphocyte protein 4
- Mechanism
- Cytotoxic T-lymphocyte protein 4 inhibitor
-
Development asset linked to Orion Laboratories Pty in public FDA and regional records.
-
Development asset linked to Orion Laboratories Pty in public FDA and regional records.
-
midazolam
Nervous system (N05)US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
nivolumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
Development asset linked to Orion Laboratories Pty in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Progesterone receptor.
- Target
- Progesterone receptor
- Mechanism
- Progesterone receptor agonist
-
US regulatory status: approved. Molecular target: Amine oxidase [flavin-containing] B.
- Target
- Amine oxidase [flavin-containing] B
- Mechanism
- Monoamine oxidase B inhibitor
-
sotorasib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: GTPase KRas.
- Target
- GTPase KRas
- Mechanism
- GTPase KRas inhibitor
-
Development asset linked to Orion Laboratories Pty in public FDA and regional records.
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
toremifene
Antineoplastic and immunomodulating agents (L02)Antineoplastic and immunomodulating agents (L02) compound in Orion Laboratories Pty's portfolio. Mechanism: Estrogen receptor modulator.
- Mechanism
- Estrogen receptor modulator
-
Development asset linked to Orion Laboratories Pty in public FDA and regional records.